Secondary Logo

Institutional members access full text with Ovid®

Endometrial Hyperplasia: A Review

Montgomery, Ben E. MD*; Daum, Gary S. MD; Dunton, Charles J. MD

Obstetrical & Gynecological Survey: May 2004 - Volume 59 - Issue 5 - p 368-378
CME PROGRAM: CATEGORY 1 CME REVIEW ARTICLES 13, 14 AND 15: CME REVIEW ARTICLE 14
Buy

Endometrial hyperplasia is a precursor to the most common gynecologic cancer diagnosed in women: endometrial cancer of endometrioid histology. It is most often diagnosed in postmenopausal women, but women at any age with unopposed estrogen from any source are at an increased risk for developing endometrial hyperplasia. Hyperplasia with cytologic atypia represents the greatest risk for progression to endometrial carcinoma and the presence of concomitant carcinoma in women with endometrial hyperplasia. Abnormal uterine bleeding is the most common presenting symptom of endometrial hyperplasia. Specific Pap smear findings and endometrial thickness per ultrasound could also suggest the diagnosis. Unopposed estrogen in women taking hormone replacement therapy increases the risk of endometrial hyperplasia. Tamoxifen has demonstrated its efficacy in treating women at risk for breast cancer, but it increases the risk of endometrial hyperplasia. The choice of treatment for endometrial hyperplasia is dependent on patient age, the presence of cytologic atypia, the desire for future childbearing, and surgical risk. Endometrial hyperplasia without atypia responds well to progestins. However, women with atypical hyperplasia should be treated with hysterectomy unless other factors preclude surgery.

Target Audience: Obstetricians & Gynecologists, Family Physicians.

Learning Objectives: After completion of this article, the reader should be able to describe the definition and classification of endometrial hyperplasia, to outline the clinical features of a patient with endometrial hyperplasia, to point out the natural history of endometrial hyperplasia, and to summarize the diagnostic options for patients with endometrial hyperplasia.

*Chief Resident, Department of Obstetrics & Gynecology, The Lankenau Hospital, Wynnewood, Pennsylvania; †Associate Pathologist, Department of Pathology, The Lankenau Hospital, Wynnewood, Pennsylvania; and ‡Professor of Obstetrics and Gynecology, Jefferson Medical College, Philadelphia, Pennsylvania, and Director, Division of Gynecologic Oncology, Albert Einstein Hospital Medical Center, Philadelphia, Pennsylvania

Chief Editor’s Note: This article is part of a series of continuing education activities in this Journal through which a total of 36 AMA/PRA category 1 credit hours can be earned in 2004. Instructions for how CME credits can be earned appear on the last page of the Table of Contents.

Reprint requests to: Ben E. Montgomery, MD, 100 Lancaster Avenue, Lankenau MOB South, Suite #301, Wynnewood, PA 19096. E-mail: benandtanyia@aol.com

The authors have disclosed no significant financial or other relationship with any commercial entity.

© 2004 Lippincott Williams & Wilkins, Inc.